Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Company Deals

Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001

Fineline Cube Aug 13, 2026
Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Fineline Cube Aug 14, 2026
Company Drug

CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included

Fineline Cube Aug 14, 2026
Company Drug

Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin

Fineline Cube Aug 14, 2026
Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Fineline Cube Feb 4, 2026

Merck & Co. (MSD, NYSE: MRK) reported full‑year 2025 revenue of USD 65.5 billion, up 2% year‑on‑year...

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026

Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Fineline Cube Feb 4, 2026

Bio-Thera Solutions (SHA: 688177) announced a licensing agreement with Avalon Pharma, granting the Saudi Arabia‑headquartered...

Company Drug

Marubeni Launches Xenleta in China After Complex Licensing Journey

Fineline Cube Feb 4, 2026

Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for...

Company Drug

CMS-D017 Gets NMPA Approval for Complement-Mediated Kidney Disease Study

Fineline Cube Feb 4, 2026

China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has...

Company Deals Drug

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

Fineline Cube Feb 4, 2026

Akeso Biopharma (HKG: 9926) announced a partnership with Jumpcan Pharmaceutical (SHA: 600566) granting Jumpcan exclusive...

Company Drug

United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial

Fineline Cube Feb 4, 2026

United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Wuhan YZY Biopharma Gets FDA Nod for M701 Phase Ib/II MPE Study

Fineline Cube Feb 4, 2026

Wuhan YZY Biopharma Co., Ltd (HKG: 2496) announced that the U.S. Food and Drug Administration...

Company

Amgen Q4 Revenue Grows 9% to $9.9B on Strong Product Sales

Fineline Cube Feb 4, 2026

Amgen (NASDAQ: AMGN) reported fourth‑quarter 2025 revenue of USD 9.9 billion, up 9% year‑over‑year (YOY), bringing full‑year revenue...

Company Deals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Fineline Cube Feb 4, 2026

Grand Pharmaceutical Group Limited (HKG: 0512) announced plans to acquire 100% equity in Hebei Grand...

Company

Novo Nordisk Sales Reach DKK 309 Billion on GLP‑1 and Obesity Surge

Fineline Cube Feb 4, 2026

Novo Nordisk (NYSE: NVO) reported 2025 global sales of DKK 309 billion (USD 48.9 billion), representing 10% year‑on‑year (YOY) growth...

Company Deals

Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug

Fineline Cube Feb 4, 2026

Simcere Pharmaceutical Group Ltd (HKG: 2096) announced it has received a USD 40 million near‑term milestone payment from...

Company Deals

Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System

Fineline Cube Feb 4, 2026

Medtronic Inc. (NYSE: MDT) announced it will exercise its option to acquire Israel-based medical device company...

Company Deals

TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline

Fineline Cube Feb 4, 2026

TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board...

Company Drug

BeBetter Med BEBT-701 Approved for Hypertension siRNA Trial

Fineline Cube Feb 4, 2026

Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced that the National Medical Products Administration...

Company Drug

AbbVie Files Rinvoq for Vitiligo Approval in US and EU

Fineline Cube Feb 4, 2026

AbbVie (NYSE: ABBV) announced it has submitted new indication applications to the U.S. Food and Drug...

Company Drug

Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer

Fineline Cube Feb 4, 2026

AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration...

Company Drug

Bayer Nubeqa Gets NMPA Approval for Metastatic Prostate Cancer

Fineline Cube Feb 4, 2026

Bayer AG (ETR: BAYN) announced that the National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide)...

Company

Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data

Fineline Cube Feb 4, 2026

Daiichi Sankyo (TYO: 4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting...

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Fineline Cube Feb 3, 2026

Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study...

Posts pagination

1 … 89 90 91 … 708

Recent updates

  • Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development
  • CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included
  • ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions
  • Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin
  • NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Company Drug

CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included

Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Company Drug

Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.